Remicade

January 31, 2017January 31, 2017

Relapse Common in IBD Patients Who Stop Anti-TNF Therapy, But Can Take Years, Study Finds

News

Nearly half of the more than 1,000 people with inflammatory bowel disease (IBD) in clinical remission had a relapse some three years after stopping anti-tumor necrosis factor (anti-TNF) treatment — and more than half relapsed ... Read more

October 27, 2016October 27, 2016

Switch to Biosimilar Inflectra from Remicade Supported by Report at 2016 UEG Week

News

Phase 4 trial results were recently presented that supported switching patients from Remicade (infliximab) to its biosimilar drug Inflectra as a safe and non-inferior alternative. The results, presented at the UEG (United European Gasroenterology) Week 2016 in ... Read more

September 19, 2016September 19, 2016

Janssen to Monitor Remicade IBD Treatment for Free in Patients

News

Janssen Biotech is partnering with Miraca Life Sciences and its InformTx therapeutic drug monitoring service to develop the Janssen 2Inform program for patients with inflammatory bowel disease (IBD) being treated with Remicade ... Read more

June 24, 2016June 24, 2016

InformTx Therapeutic Drug Monitoring for IBD Patients Launched by Miraca Life Sciences

IBD News, News

Miraca Life Sciences, an independent anatomic pathology lab based in Irving, Texas, is expanding into clinical pathology testing for patients with inflammatory bowel disease (IBD). Miraca’s new InformTx therapeutic drug monitoring ... Read more

June 9, 2016August 12, 2016

IBD Study Shows Celltrion’s Inflectra, Biosimilar of Infliximab, Is Safe and Effective

Crohn's Disease, IBD News, News, Ulcerative colitis

Celltrion’s Inflectra, a biosimilar version of infliximab (Remicade), is both safe and effective in patients with inflammatory bowel disease (IBD), a recent study reported at the Digestive Disease Week 2016 meeting ... Read more

April 13, 2016September 28, 2016

Celltrion’s Inflectra, a Biosimilar to Treat Ulcerative Colitis and Crohn’s Disease, Gets FDA Approval

News

Celltrion recently announced it has received approval from the U.S. Food and Drug Administration (FDA) for the use of its Inflectra (biosimilar infliximab) product for all indications of the reference product, ... Read more

April 11, 2016April 11, 2016

FDA Approves Inflectra, a Biosimilar to Remicade, to Treat Ulcerative Colitis and Crohn’s

News

Celltrion announced that the U.S. Food and Drug Administration (FDA) approved Inflectra (biosimilar infliximab) for all indications of the reference product Remicade (infliximab), marketed in the country by Janssen Biotech, Inc. ... Read more

April 6, 2016April 6, 2016

CHMP Issues Positive Opinion on Samsung Bioepis’ Flixabi, a Biosimilar Treatment for IBD

Crohn's Disease, IBD News, News, Ulcerative colitis

The Committee for Medicinal Products for Human Use (CHMP), the scientific board of European Medicines Agency, has issued a positive opinion on Samsung Bioepis’ Flixabi for the treatment of ulcerative colitis (UC) ... Read more

February 12, 2016February 12, 2016

First Biosimilar Therapy for Crohn’s Disease and Ulcerative Colitis Is Focus of FDA Meeting

Crohn's Disease, IBD News, News, Ulcerative colitis

The U.S. Food and Drug Administration (FDA) Arthritis Advisory Committee recently met to review a biologics license application (BLA) submitted by Celltrion Inc. for its compound CT-P13, a proposed biosimilar to Remicade ... Read more

August 21, 2015August 21, 2015

Remicade Biosimilar Inflectra Now Registered in Australia for Crohn’s Disease, Ulcerative Colitis

News

Hospira, Inc. has just announced its leading monoclonal antibody (mAb) biosimilar therapy, Inflectra, is now registered in Australia as a treatment of 8 inflammatory diseases, including: rheumatoid arthritis (RA); psoriatic ... Read more